These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 15650310)

  • 1. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
    Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
    Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
    Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
    Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
    Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
    Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
    Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.
    Savolainen J; Jacobsen L; Valovirta E
    Allergy; 2006 Oct; 61(10):1184-90. PubMed ID: 16942566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
    Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
    J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.
    Lima MT; Wilson D; Pitkin L; Roberts A; Nouri-Aria K; Jacobson M; Walker S; Durham S
    Clin Exp Allergy; 2002 Apr; 32(4):507-14. PubMed ID: 11972594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
    Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
    Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose dependence of immunological response to sublingual immunotherapy.
    Marcucci F; Sensi L; Di Cara G; Incorvaia C; Frati F
    Allergy; 2005 Jul; 60(7):952-6. PubMed ID: 15932387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.